Zydus Lifesciences is currently trading at RS 909.60, up by 22.05 points or 2.48% from its previous closing of RS 887.55 on the BSE.

The stock opened at RS 947.95 and recorded a high and low of RS 947.95 and RS 905.00, respectively. A total of 96,931 shares have been traded so far. The stock, with a face value of RS 1, reached a 52-week high of RS 1323.90 on 09-Aug-2024 and a 52-week low of RS 859.15 on 04-Mar-2025. The company's market capitalization stands at RS 92,090.53 crore.

The promoter holding in Zydus Lifesciences is 74.98%, while institutions and non-institutions hold 18.18% and 6.84%, respectively.

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Dasatinib Tablets in various strengths (20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg). Dasatinib is used for the treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as for patients with resistance or intolerance to prior therapies, including imatinib. The drug will be manufactured at Zydus Lifesciences' SEZ facility in Ahmedabad.

The annual sales of Dasatinib tablets in the US stood at $1807.7 million (IQVIA MAT January 2025). Zydus Lifesciences has now received 415 approvals and has filed 483 Abbreviated New Drug Applications (ANDAs) since FY 2003-04.

Zydus Lifesciences, formerly known as Cadila Healthcare, is an integrated pharmaceutical company involved in research, development, production, marketing, and distribution of pharmaceutical products.